Article info

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy

Authors

  1. Correspondence to Professor Min Xiao; xiaomin{at}tjh.tjmu.edu.cn; Professor Yi Xiao; yixiao{at}tjh.tjmu.edu.cn

Citation

Wang J, Shang Z, Wang J, et al
MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy

Publication history

  • Accepted April 18, 2021
  • First published June 1, 2021.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.